Ultragenyx and Mereo impress with setrusumab showing

Shares in both US biopharma Ultragenyx (Nasdaq: RARE) and UK-based Mereo BioPharma (Nasdaq: MREO) closed around 8% higher on Wednesday, as companies earlier shared positive 14-month results from the Phase II portion of the ongoing Phase II/III Orbit study.

This data demonstrated that, as of a May 24, 2024 data cut-off date, treatment with setrusumab (UX143) continued to significantly reduce incidence of fractures in patients with osteogenesis imperfecta (OI) with at least 14 months of follow-up.

"New and stronger bone is being created that has resulted in an important reduction in fractures"Treatment with setrusumab also resulted in ongoing and meaningful improvements in lumbar spine bone mineral density (BMD) at month 12 without evidence of plateau.